Jun 2026 (Q2 FY26) — Aug 6, 2026
Encompass Health Q2 FY26 — Strong Growth and Raised Full-Year Guidance
Read the full callEncompass Health (EHC) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Encompass Health earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1,597 | +9.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | 154 | +8.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$121.71 −4.82% · −$6.16
Performance −2.3% 1Y
1Y: $124.55 on 17 Oct 2025 → $121.71. High $127.87 (16 Oct 2026), low $93.83 (2 Feb 2026).
- Previous close
- $127.87
- 52-week range
- $93.83 – $127.87
- One year
- −2.79%
Overview
- Symbol
- EHC
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 1, 2026
Encompass Health Q1 FY26 — Strong Performance and Raised Guidance
Read the full callEvery analysed call
Encompass Health earnings calls (EHC)
Financials
What the filings say
Net profit, year on year: +8% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,351 | 1,405 | 1,455 | 1,458 | 1,478 | 1,545 | 1,587 | 1,597 |
| Expenses | 1,142 | 1,173 | 1,188 | 1,199 | 1,234 | 1,261 | 1,285 | 1,309 |
| Interest | 35 | 33 | 32 | 30 | 31 | 30 | 32 | 33 |
| Profit before tax | 184 | 201 | 239 | 237 | 220 | 258 | 289 | 262 |
| Tax rate | 19.6% | 18.7% | 17.4% | 21.5% | 20.4% | 21.5% | 19.5% | 20.5% |
| Net profit | 108 | 121 | 152 | 142 | 127 | 146 | 195 | 154 |
| EPS ($ per share) | 1.08 | — | 1.50 | 1.41 | 1.26 | — | 1.96 | 1.55 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reserves | -885 | -526 | -242 | 142 | 116 | 407 | 797 | 1,289 |
| Total liabilities | 3,356 | 4,148 | 4,444 | 4,466 | 3,775 | 3,805 | 3,686 | 3,814 |
| Fixed assets | 1,635 | 1,959 | 2,207 | 2,581 | 2,939 | 3,301 | 3,643 | 4,102 |
| Total assets | 5,175 | 6,081 | 6,446 | 6,865 | 5,637 | 6,102 | 6,535 | 7,090 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 762 | 635 | 705 | 716 | 706 | 851 | 1,003 | 1,176 |
| Cash from investing | -424 | -657 | -407 | -666 | -627 | -603 | -653 | -765 |
| Cash from financing | -321 | 48 | -146 | -240 | -146 | -197 | -331 | -431 |
| Net cash flow | 17 | 26 | 151 | -191 | -67 | 51 | 19 | -20 |
| Capital expenditure | -254 | -372 | -393 | -525 | -565 | -583 | -642 | -736 |
| Free cash flow | 508 | 263 | 312 | 191 | 141 | 268 | 360 | 439 |
EHC revenue by segment
| Segment | Q2 FY2024 | Q3 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Inpatient Rehabilitation | — | — | 100% | 100% | 100% | 100% | 100% | 100% | +9.6% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
EHC operating KPIs by quarter
| KPI | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Discharge acute rate | 8.6%Our discharge acute rate improved 30 basis points to 8.6%, and our discharge to SNF rate improved 20 basis points to 6.2%.Source: earnings call transcript | 8.4%Discharge to acute rate was 8.4% and discharge to skilled nursing facilities was 6.1%.Source: earnings call transcript | -0.2 pt |
| Discharge to SNF rate | 6.2%Our discharge acute rate improved 30 basis points to 8.6%, and our discharge to SNF rate improved 20 basis points to 6.2%.Source: earnings call transcript | 6.1%Discharge to acute rate was 8.4% and discharge to skilled nursing facilities was 6.1%.Source: earnings call transcript | -0.1 pt |
| Annualized RN turnover | 17.8%We believe our success in these programs contribute to the continuing improvement in our clinical staff turnover trends Q1 2016 annualized RN turnover was 17.8%, down from fiscal year '25 to 20.2% and annualized therapist turnover was 6.4%, down from last year's 7.8%.Source: earnings call transcript | ~19%So on an annualized basis through Q2, our nursing turnover sits around 19%.Source: earnings call transcript | — |
| Annualized therapist turnover | 6.4%We believe our success in these programs contribute to the continuing improvement in our clinical staff turnover trends Q1 2016 annualized RN turnover was 17.8%, down from fiscal year '25 to 20.2% and annualized therapist turnover was 6.4%, down from last year's 7.8%.Source: earnings call transcript | 7%+On the therapy perspective, we're just above 7%.Source: earnings call transcript | — |
| Contract labor FTEs as a percent of total FTEs | 1.2%Contract labor FTEs as a percent of total FTEs was 1.2% in Q1, down 10 basis points from Q1 '25.Source: earnings call transcript | 1.1%Contract labor FTEs as a percent of total FTEs was 1.1% and an improvement of 20 basis points from Q2 '25.Source: earnings call transcript | -0.1 pt |
| Average occupancy rate | 78.7%Our Q1 average occupancy of 78.7% was essentially flat with our record high levels in Q1 of '25 and that was up 200 basis points from Q1 of '24 and up over 500 basis points from Q1 of '23.Source: earnings call transcript | 77.4%To put a finer point on that, our Q2 occupancy of 77.4% was up 290 basis points over Q2 '25.Source: earnings call transcript | -1.3 pt |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Insider filings
105 filings between Jan 15, 2026 and Aug 31, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$47.79M
18 sales by 6 insiders
Compensation
not trading decisions- 56
- Award — granted as compensation
- 2
- Option exercise — converted options into shares
- 28
- Tax withheld — shares kept back by the company to cover tax
Also filed: 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Tarr Mark J | — | $38.47M | Aug 10, 2026 |
| COLTHARP DOUGLAS E | — | $5.32M | Aug 10, 2026 |
| Darby John Patrick | — | $1.71M | Aug 31, 2026 |
| Fay Edmund | — | $1.28M | Mar 9, 2026 |
| Price Andrew L | — | $630.2K | Aug 31, 2026 |
| Tuer Patrick William | — | $373.1K | May 11, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 31, 2026 | Darby John Patrick EVP, Gen Counsel & Secretary | Option exercise | 4,858 | $170.3K |
| Aug 31, 2026 | Darby John Patrick EVP, Gen Counsel & Secretary | Sale | 4,858 | $588.3K |
| Aug 31, 2026 | Price Andrew L Chief Accounting Officer | Sale | 5,211 | $630.2K |
| Aug 10, 2026 | Darby John Patrick EVP, Gen Counsel & Secretary | Sale | 8,906 | $1.12M |
| Aug 10, 2026 | Tarr Mark J President & CEO | Sale | 171,569 | $21.53M |
| Aug 10, 2026 | Tarr Mark J President & CEO | Sale | 1,579 | $199.0K |
| Aug 10, 2026 | COLTHARP DOUGLAS E EVP & Chief Financial Officer | Sale | 18,869 | $2.37M |
| Jul 16, 2026 | Christie Edward M III Director | Award | 248 | $27.9K |
| Jul 16, 2026 | Reidy Christopher R Director | Award | 319 | $35.9K |
| Jul 15, 2026 | Reidy Christopher R Director | Award | 21 | $0 |
| Jul 15, 2026 | Christie Edward M III Director | Award | 11 | $0 |
| Jul 15, 2026 | Williams Terrance Director | Award | 29 | $0 |
| Jul 15, 2026 | CARMICHAEL GREG D Director | Award | 29 | $0 |
| Jul 15, 2026 | HERMAN JOAN E Director | Award | 85 | $0 |
| Jul 15, 2026 | Hayes Cain A Director | Award | 4 | $0 |
| Jul 15, 2026 | O'Connor Kevin J. Director | Award | 19 | $0 |
| Jul 15, 2026 | KATZ LESLYE G Director | Award | 85 | $0 |
| Jul 15, 2026 | SCHLICHTING NANCY M Director | Award | 40 | $0 |
| May 15, 2026 | COLTHARP DOUGLAS E EVP & Chief Financial Officer | Option exercise | 27,694 | $912.2K |
| May 15, 2026 | COLTHARP DOUGLAS E EVP & Chief Financial Officer | Sale | 1 | $107 |
| May 15, 2026 | COLTHARP DOUGLAS E EVP & Chief Financial Officer | Sale | 27,693 | $2.96M |
| May 11, 2026 | Tuer Patrick William EVP, Chief Operating Officer | Sale | 682 | $71.3K |
| May 7, 2026 | SCHLICHTING NANCY M Director | Award | 1,634 | $0 |
| May 7, 2026 | O'Connor Kevin J. Director | Award | 1,634 | $0 |
| May 7, 2026 | Christie Edward M III Director | Award | 1,634 | $0 |
| May 7, 2026 | Reidy Christopher R Director | Award | 1,634 | $0 |
| May 7, 2026 | Hayes Cain A Director | Award | 1,634 | $0 |
| May 7, 2026 | Williams Terrance Director | Award | 1,634 | $0 |
| May 7, 2026 | KATZ LESLYE G Director | Award | 1,634 | $0 |
| May 7, 2026 | CARMICHAEL GREG D Director | Award | 1,634 | $0 |
| May 7, 2026 | HERMAN JOAN E Director | Award | 1,634 | $0 |
| Apr 16, 2026 | Christie Edward M III Director | Award | 261 | $27.7K |
| Apr 16, 2026 | Reidy Christopher R Director | Award | 334 | $35.6K |
| Apr 15, 2026 | Reidy Christopher R Director | Award | 19 | $0 |
| Apr 15, 2026 | SCHLICHTING NANCY M Director | Award | 39 | $0 |
| Apr 15, 2026 | O'Connor Kevin J. Director | Award | 17 | $0 |
| Apr 15, 2026 | Williams Terrance Director | Award | 27 | $0 |
| Apr 15, 2026 | CARMICHAEL GREG D Director | Award | 27 | $0 |
| Apr 15, 2026 | Christie Edward M III Director | Award | 9 | $0 |
| Apr 15, 2026 | Hayes Cain A Director | Award | 1 | $0 |
| Apr 15, 2026 | HERMAN JOAN E Director | Award | 85 | $0 |
| Apr 15, 2026 | KATZ LESLYE G Director | Award | 85 | $0 |
| Mar 9, 2026 | Fay Edmund Sr. Vice Pres. and Treasurer | Sale | 11,937 | $1.28M |
| Mar 9, 2026 | Fay Edmund Sr. Vice Pres. and Treasurer | Gift | 3,000 | $0 |
| Feb 28, 2026 | Price Andrew L Chief Accounting Officer | Tax withheld | 307 | $33.1K |
| Feb 28, 2026 | COLTHARP DOUGLAS E EVP & Chief Financial Officer | Tax withheld | 776 | $83.7K |
| Feb 28, 2026 | Fay Edmund Sr. Vice Pres. and Treasurer | Tax withheld | 280 | $30.2K |
| Feb 28, 2026 | Charbonneau Elissa Joy Chief Medical Officer | Tax withheld | 369 | $39.8K |
| Feb 28, 2026 | Darby John Patrick EVP, Gen Counsel & Secretary | Tax withheld | 416 | $44.9K |
| Feb 28, 2026 | Tarr Mark J President & CEO | Tax withheld | 2,187 | $235.9K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Encompass Health Corp
Free account. Everything above stays public.
Write why you follow Encompass Health Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading